Tushar Shah - Nov 10, 2021 Form 4 Insider Report for Liquidia Corp (LQDA)

Role
CMO and Head of R&D
Signature
/s/ Russell Schundler, as attorney-in-fact for Dr. Tushar Shah
Stock symbol
LQDA
Transactions as of
Nov 10, 2021
Transactions value $
-$60,661
Form type
4
Date filed
11/12/2021, 08:03 PM
Previous filing
Jul 23, 2021
Next filing
Jan 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LQDA Common Stock Options Exercise +51.3K 51.3K Nov 10, 2021 Direct F1
transaction LQDA Common Stock Tax liability -$2.46K -487 -0.95% $5.05 50.8K Nov 12, 2021 Direct
transaction LQDA Common Stock Tax liability -$58.2K -11.9K -23.41% $4.90 38.9K Nov 12, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LQDA Performance Stock Units Award $0 -51.3K -100% $0.00* 0 Nov 10, 2021 Common Stock 51.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit (PSU) converts into one share of common stock of the Issuer.
F2 On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861.

Remarks:

Exhibit 24 - Power of Attorney